
FIGS. 1A-1C


		Binding # Isolates		Immunogenicity (SU)			
		Amino Acid Sequence IC50				10 100 1000 10000	
Δ	<u>P</u>		.0 134	19	55	Biography State (SH	
11.	. А		1.2 2			0.00 (2100 0 - 100 0 100	
			1.7 1 0.3 1		1		
	NA		.6 3		3		
	,		.6 5	1	•	-7777	
			90 3	1		b	
		K L T F L C V T L 19	.4 1				
			.0 1		1		
			.8 1		1		
		h	.3 1				
			7.0 1 .7 1				
			.6 1	1			
			.2 1	•			
			3.6				
			5.2 1				
	М		5.9 1				
			53 3				
		KMTFLCVQM 17	93 1			7	
						10 100 1000 10000	
-	Р	VLAEAMSQV 49	.9 54	15	3	District District Co. Co.	
В.	A	VLAEAMS QA 23	.8 · 67		36	**************************************	
		VLAEAMSQT 28	9.6 11		9		
		VLAEAMSQI 70		1			
	NA		.0 5	3			
		VLAEAMGQV 55 VLAEAMSRV 39			1		
		VLAEAMSKV 23		1	1		
		VLAEAMSHV 29			•		
	M	ALAEAMSQA 15	.0 1		1		
			.3 3		2		
		VLGEAMSQA 17			1	<u> </u>	
		VLAEAMSKA 69			1		
		VLAEAMSRA 12 VLAEAMSHA 14			4		
		VLAEAMSHT 24			1		
		VLAEAMSAA 23			•	B-	
		VLAEAMATA 6					
		V L A E A M A A A 17	.2 1			TH TH	
	!	I LAEAMSKA 72			1		
		ILAEAMASA 22	.2 1				
					1	10 100 1000 10000	
\boldsymbol{C}	Р	RILQQLLFI 72	.5 86	15 2	28		
C.	A	RLLQQLLFI 27			1		
		RTLQQLLFI 15	1.6 10	2	4		
		RMLQQLLFI 14	.7 4	1	3		
		RVLQQLLFI 27			3		
		RILQQLLFV 27			2		
		RILQQLLFT 14 RILQQLLFA 122			2		
	NA	KILQQLLFI 40			1		
		TILQQLLFI 94			•		
		RILQQMLFI 186					
		RILQQPLFI 140).1 , 1		1	·	
		RILQQLLLI 199		_1			
	М	RVLQQLLFV 10			1	· · · · · · · · · · · · · · · · · · ·	
		RMLQQLLFV 21 RMLQQLLFT 125			_		
		RMLQQLLFT 125 RTLQQLLFA 948			1		
		RTLQQLLFT 97		1			
		RTLQQLLFV 120		•	1	·	
		RTLQQLMFI 143			i		
		RMLQHLLFI 15			1	⊒⊣	
		RILQHLLFA 160					
		RILQRLLFV 64			1		
		RTLQLLLEV 4.	7 1				


FIGS. 1D-1E

		Binding	# Iso			Immunogenicity (
	Amino Acid Sequence	IC50 (nM)	Total		10	100 100	0 10000
D.	PVTIKIGGQLK	15.5		13 1		ا-⊟لعثامات عند	
1 .	AVAIKIGGQLK	151.3	2	1	F		
	VTIKIGGQLR	64.0	2			(A) (C) (C) (C)	
	NAVTVKIGGQLK	60.7	11	1	E		•
	VTIRIGGQLK	14.4		2	<u> </u>		
	VTIKVGGQLK	59.4	2	2	<u> </u> =		
	VTIKIEGQLK	69.4	2	1	=		
	VTIKIGGQIK	183.5	1				
	2NA V T V K I G G Q L R	194.1	3		Ξ		
	VTVKIGGELK	39.2	1		F		
	VTVKIEGQLK	23.2	4		į.		
	VTVKVGGQLK	54.3	3		<u> </u>	**************************************	
	VTVRIGGQLK	15.2	6		<u> </u> =		
	VTIRIGGQLR	22.9	2		F		
	VTIRVGGQLK	13.2	1		₽	4	
	VAIKIGGQIK	940.2	1	1			
	VNIKVGGQLK	1768	1	1	<u>}</u>		
	VTIKIGGQIR	388.5	1				
	3NA V T I K L G G Q I R	219.5	1		<u> </u>	1	
	VTVKIEGQLR	143.0	4		Ľ	-	
	VTVKVGGQLR	198.7	2		F		
	VTIRVGGQLR	17.3	1			1	
	VSIKVGGQIK	85.9	30	30	i.	- 	
	VTVRVGGQLK	19.3	1				
	4NA V T I R V A G Q V K	20:8	1 .	•	· .		
	VSIRVGGQTK	20.9	1		r		
	VSIRVGGQIK	90.6	4	4	ł		
	VSIKVGGQIR	1339	6	6	1		
	VTVRIGGMQK	13.4	1	_	i		
	VSIRVGGQTR	240.6	1	1	Į.		
	ITVKIGKEVR	12904	1		,		
					10	100 1000	10000
173	PVTVYYGVPVWK	9.2	00 1		1=	· · · · · · · · · · · · · · · · · · ·	
E.	AVTVYYGVPVWF		99 2 40	1 30			
	NAVTIYOV		1	18			
	VTVYDGVPVWK		1	4			
	VTVYGVPIWK		2	1			
	MITVYYGVPVWR		1		<u>=</u>		
	VTIYYGVPVWR		1				
•	VTVYDGVPVWR		1	1	111		
	VTVYGIPVWR		1	•	2		
	VTVYYGVPVRR		1		<u> </u>		
			•				

FIGS. 2A-2C







FIGS. 3A-3B




FIG. 4

	Binding	· · · · · · · · · · · · · · · · · · ·	Predicted Cr	ose-mactivity		Immun	ogoploty (CLI)	
Amino Acid Sequence	IC ₅₀ (nM)	# Isolates	Predicted Cross-rea solates MTNNPPIPV MTSN		10	Immunogenicity (SU) 100 1000 10000		
MTSNPPIPV	52.8	60		+				
MINNPPIPV	128.4	33	+	+			≒ ⊸	
MTSNPPVPV	21.8	26	-	+	<u> </u>		4	
ATGNPP I PV	125.1	15	-	+			13-4	
ATGNPPVPV	2021	9	-	+	<u> </u>			
M T N N P P V P V	85.6	6	+	+	<u> </u>			
ATANPP V PV	20.0	3	-	+	<u> </u>			
ATHNPPIPV,	167.0	2	+	-		⊔.		
ITANPPIPV	2.3	1	-	+	<u> </u>		3-1	
ATS DPPIPV	107.4	1	-	+		H		
TGNPSIPV	15.8	1	-	+	. ⊢			
ITGNPAIPV	1200	1	-	+	j			
ITSNPAIPV	1465	1	_	+]===	3 H	■ MTNNPPIPV □ MTSNPPIPV	
MTRNPPVPV	9171	1	_	-]			